Literature DB >> 9305317

Dopamine and migraine.

S J Peroutka1.   

Abstract

This review summarizes a growing body of biological, pharmacologic, and genetic data that support a role for dopamine in the pathophysiology of certain subtypes of migraine. Most migraine symptoms can be induced by dopaminergic stimulation. Moreover, there is dopamine receptor hypersensitivity in migraineurs, as demonstrated by the induction of yawning, nausea, vomiting, hypotension, and other symptoms of a migraine attack by dopaminergic agonists at doses that do not affect nonmigraineurs. Conversely, dopamine receptor antagonists are effective therapeutic agents in migraine. Recent genetic data suggest that molecular variations within dopamine receptor genes play a modifying role in the pathophysiology of migraine with aura. Therefore, modulation of dopaminergic neurotransmission should be considered in the therapeutic management of migraine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305317     DOI: 10.1212/wnl.49.3.650

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

Review 1.  White matter hyperintensities: from medical comorbidities to bipolar disorders and back.

Authors:  Eva Gunde; Ryan Blagdon; Tomas Hajek
Journal:  Ann Med       Date:  2011-07-13       Impact factor: 4.709

2.  Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia.

Authors:  R Kagan; V Kainz; R Burstein; R Noseda
Journal:  Neuroscience       Date:  2013-06-25       Impact factor: 3.590

Review 3.  Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction.

Authors:  Johanna M Jarcho; Emeran A Mayer; Ziyue Karen Jiang; Natasha A Feier; Edythe D London
Journal:  Pain       Date:  2012-03-03       Impact factor: 6.961

4.  Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

Authors:  I Rainero; W Valfrè; L Savi; S Gentile; L Pinessi; L Gianotti; E Arvat; E Ghigo; P Del Rizzo; P Calvelli; P Limone
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

5.  Parental and comorbid migraine in individuals with bipolar disorder: A nationwide register study.

Authors:  Dan Sucksdorff; Alan S Brown; Roshan Chudal; Markus Heinimaa; Auli Suominen; Andre Sourander
Journal:  J Affect Disord       Date:  2016-07-19       Impact factor: 4.839

6.  Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin.

Authors:  Fabiano C Tanuri; Eliângela de Lima; Mario F P Peres; Francisco R Cabral; Maria da Graça Naffah-Mazzacoratti; Esper Abrão Cavalheiro; José Cipolla-Neto; Eliova Zukerman; Débora Amado
Journal:  J Headache Pain       Date:  2009-01-27       Impact factor: 7.277

7.  Association between migraine and a functional polymorphism at the dopamine beta-hydroxylase locus.

Authors:  F Fernandez; N Colson; S Quinlan; J MacMillan; R A Lea; L R Griffiths
Journal:  Neurogenetics       Date:  2009-02-14       Impact factor: 2.660

8.  Diagnosing and managing headache in children.

Authors:  Paul Winner; Scott W Powers; Marielle A Kabbouche; Andrew D Hershey
Journal:  Curr Treat Options Neurol       Date:  2007-01       Impact factor: 3.598

Review 9.  Headache and sleep in children.

Authors:  Benedetta Bellini; Sara Panunzi; Oliviero Bruni; Vincenzo Guidetti
Journal:  Curr Pain Headache Rep       Date:  2013-06

Review 10.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.